| 1 | Prognostic value of single-subject grey matter networks in early multiple sclerosisBrain, 2024, 147, 135-146 | 8.9 | 8 | Citations (PDF) |
| 2 | B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans | 13.1 | 6 | Citations (PDF) |
| 3 | Long-Term Observation of SARS-CoV-2 Vaccination Response upon High Efficacy Treatment in Multiple Sclerosis—A Real-World Scenario | 3.1 | 0 | Citations (PDF) |
| 4 | Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories | 13.1 | 7 | Citations (PDF) |
| 5 | Altered cortical synaptic lipid signaling leads to intermediate phenotypes of mental disorders | 8.3 | 2 | Citations (PDF) |
| 6 | Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis | 3.7 | 0 | Citations (PDF) |
| 7 | Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis | 10.0 | 1 | Citations (PDF) |
| 8 | Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort | 7.1 | 5 | Citations (PDF) |
| 9 | Implications of immunometabolism for smouldering MS pathology and therapy | 9.2 | 1 | Citations (PDF) |
| 10 | Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis | 7.1 | 27 | Citations (PDF) |
| 11 | Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis | 6.6 | 19 | Citations (PDF) |
| 12 | Inhibition of the enzyme autotaxin reduces cortical excitability and ameliorates the outcome in stroke | 13.1 | 26 | Citations (PDF) |
| 13 | Preventing disease progression in multiple sclerosis—insights from large real-world cohorts | 9.9 | 2 | Citations (PDF) |
| 14 | Interleukin-4 receptor signaling modulates neuronal network activity | 8.1 | 19 | Citations (PDF) |
| 15 | Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies | 2.1 | 17 | Citations (PDF) |
| 16 | Network alterations underlying anxiety symptoms in early multiple sclerosis | 9.2 | 11 | Citations (PDF) |
| 17 | Progression in multiple sclerosis – a long-term problem | 4.1 | 6 | Citations (PDF) |
| 18 | T cell–neuron interaction in inflammatory and progressive multiple sclerosis biology | 5.0 | 12 | Citations (PDF) |
| 19 | Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers | 3.8 | 23 | Citations (PDF) |
| 20 | Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug‐resistant epilepsy | 4.8 | 32 | Citations (PDF) |
| 21 | Implications of extreme serum neurofilament light chain levels for the management of patients with relapsing multiple sclerosis | 3.7 | 4 | Citations (PDF) |
| 22 | Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper) | 3.7 | 124 | Citations (PDF) |
| 23 | Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis | 3.7 | 9 | Citations (PDF) |
| 24 | Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis | 7.1 | 22 | Citations (PDF) |
| 25 | The neuroinflammation collection: a vision for expanding neuro-immune crosstalk in BrainBrain, 2021, 144, e59-e59 | 8.9 | 5 | Citations (PDF) |
| 26 | Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp> | 6.6 | 35 | Citations (PDF) |
| 27 | The potential of serum neurofilament as biomarker for multiple sclerosisBrain, 2021, 144, 2954-2963 | 8.9 | 134 | Citations (PDF) |
| 28 | Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose | 0.3 | 4 | Citations (PDF) |
| 29 | Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions | 4.0 | 5 | Citations (PDF) |
| 30 | Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) | 0.9 | 16 | Citations (PDF) |
| 31 | Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 | 7.1 | 76 | Citations (PDF) |
| 32 | Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions | 2.6 | 12 | Citations (PDF) |
| 33 | Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation | 7.7 | 44 | Citations (PDF) |
| 34 | NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study | 10.0 | 34 | Citations (PDF) |
| 35 | Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunityBrain, 2021, 144, 3126-3141 | 8.9 | 23 | Citations (PDF) |
| 36 | Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders | 3.7 | 27 | Citations (PDF) |
| 37 | Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity | 7.7 | 50 | Citations (PDF) |
| 38 | Genetic determinants of the humoral immune response in MS | 7.1 | 7 | Citations (PDF) |
| 39 | The frequency of follicular T helper cells differs in acute and chronic neuroinflammation | 3.7 | 7 | Citations (PDF) |
| 40 | Functional characteristics of Th1, Th17, and ex-Th17 cells in EAE revealed by intravital two-photon microscopy | 9.2 | 33 | Citations (PDF) |
| 41 | CNS-localized myeloid cells capture living invading T cells during neuroinflammation | 8.1 | 23 | Citations (PDF) |
| 42 | Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement | 1.0 | 5 | Citations (PDF) |
| 43 | Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study | 10.0 | 90 | Citations (PDF) |
| 44 | Is
<i>APOE</i>
ε4 associated with cognitive performance in early MS? | 7.1 | 12 | Citations (PDF) |
| 45 | Growth-Promoting Treatment Screening for Corticospinal Neurons in Mouse and Man | 4.1 | 2 | Citations (PDF) |
| 46 | Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS | 7.1 | 21 | Citations (PDF) |
| 47 | The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis | 4.8 | 1 | Citations (PDF) |
| 48 | Continuous reorganization of cortical information flow in multiple sclerosis: A longitudinal fMRI effective connectivity study | 3.7 | 20 | Citations (PDF) |
| 49 | Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS | 7.1 | 19 | Citations (PDF) |
| 50 | Ocrelizumab initiation in patients with MS | 7.1 | 32 | Citations (PDF) |
| 51 | Transient enlargement of brain ventricles during relapsing-remitting multiple sclerosis and experimental autoimmune encephalomyelitis | 5.5 | 15 | Citations (PDF) |
| 52 | β1-Integrin– and KV1.3 channel–dependent signaling stimulates glutamate release from Th17 cells | 9.1 | 36 | Citations (PDF) |
| 53 | Diagnostik und Therapie von Tuberkulose unter Immuntherapien für Multiple Sklerose | 0.9 | 3 | Citations (PDF) |
| 54 | Imaging in mice and men: Pathophysiological insights into multiple sclerosis from conventional and advanced MRI techniques | 6.0 | 21 | Citations (PDF) |
| 55 | NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke | 6.2 | 103 | Citations (PDF) |
| 56 | Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility | 38.2 | 753 | Citations (PDF) |
| 57 | Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis | 2.1 | 9 | Citations (PDF) |
| 58 | Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis | 3.7 | 26 | Citations (PDF) |
| 59 | Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging | 3.5 | 72 | Citations (PDF) |
| 60 | Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis | 9.2 | 23 | Citations (PDF) |
| 61 | Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration | 2.5 | 10 | Citations (PDF) |
| 62 | Immunoneuropsychiatry — novel perspectives on brain disorders | 9.2 | 309 | Citations (PDF) |
| 63 | Meilenstein oder verpasste Chance? | 0.9 | 0 | Citations (PDF) |
| 64 | Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS | 7.1 | 14 | Citations (PDF) |
| 65 | IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis | 14.1 | 75 | Citations (PDF) |
| 66 | Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis | 4.1 | 18 | Citations (PDF) |
| 67 | Graph Theoretical Framework of Brain Networks in Multiple Sclerosis: A Review of Concepts | 2.5 | 110 | Citations (PDF) |
| 68 | Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis | 4.1 | 15 | Citations (PDF) |
| 69 | Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis | 4.1 | 158 | Citations (PDF) |
| 70 | Characterizing Microstructural Tissue Properties in Multiple Sclerosis with Diffusion MRI at 7 T and 3 T: The Impact of the Experimental Design | 2.5 | 50 | Citations (PDF) |
| 71 | EGFL7 reduces CNS inflammation in mouse | 14.1 | 34 | Citations (PDF) |
| 72 | Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation | 13.1 | 49 | Citations (PDF) |
| 73 | Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies? | 3.2 | 8 | Citations (PDF) |
| 74 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis | 4.1 | 505 | Citations (PDF) |
| 75 | CCR7 on CD4+ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis | 0.6 | 24 | Citations (PDF) |
| 76 | Treatment choices and neuropsychological symptoms of a large cohort of early MS | 7.1 | 52 | Citations (PDF) |
| 77 | Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS | 4.1 | 51 | Citations (PDF) |
| 78 | Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria | 2.0 | 22 | Citations (PDF) |
| 79 | Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis | 12.4 | 52 | Citations (PDF) |
| 80 | EGFL7 – a potential therapeutic target for multiple sclerosis? | 3.9 | 1 | Citations (PDF) |
| 81 | Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis RiskCell, 2018, 175, 1679-1687.e7 | 35.1 | 117 | Citations (PDF) |
| 82 | Targeting prohibitins at the cell surface prevents Th17‐mediated autoimmunity | 7.4 | 16 | Citations (PDF) |
| 83 | Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging | 3.4 | 5 | Citations (PDF) |
| 84 | GFAPα IgG-associated encephalitis upon daclizumab treatment of MS | 7.1 | 43 | Citations (PDF) |
| 85 | AAN unveils new guidelines for MS disease-modifying therapy | 9.2 | 9 | Citations (PDF) |
| 86 | DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis | 14.1 | 141 | Citations (PDF) |
| 87 | Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS) | 3.4 | 28 | Citations (PDF) |
| 88 | Risikomanagement und alltagspraktische Aspekte 2018, , 361-369 | | 0 | Citations (PDF) |
| 89 | Neue, experimentelle und zukünftige Therapieansätze 2018, , 353-359 | | 0 | Citations (PDF) |
| 90 | Increased structural white and grey matter network connectivity compensates for functional decline in early multiple sclerosis | 4.1 | 60 | Citations (PDF) |
| 91 | An improved anatomical MRI technique with suppression of fixative fluid artifacts for the investigation of human postmortem brain phantoms | 3.1 | 1 | Citations (PDF) |
| 92 | A “kissing lesion”: In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis | 4.1 | 14 | Citations (PDF) |
| 93 | Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis | 7.1 | 66 | Citations (PDF) |
| 94 | Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis | 0.6 | 106 | Citations (PDF) |
| 95 | Dendritic cells tip the balance towards induction of regulatory T cells upon priming in experimental autoimmune encephalomyelitis | 6.8 | 19 | Citations (PDF) |
| 96 | Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment | 4.1 | 15 | Citations (PDF) |
| 97 | The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis | 4.5 | 26 | Citations (PDF) |
| 98 | A Novel Cervical Spinal Cord Window Preparation Allows for Two-Photon Imaging of T-Cell Interactions with the Cervical Spinal Cord Microvasculature during Experimental Autoimmune Encephalomyelitis | 5.0 | 29 | Citations (PDF) |
| 99 | Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation | 5.5 | 20 | Citations (PDF) |
| 100 | Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS | 3.0 | 63 | Citations (PDF) |
| 101 | Assessment of cortical damage in early multiple sclerosis with quantitative <i>T</i><sub>2</sub> relaxometry | 2.7 | 34 | Citations (PDF) |
| 102 | <i>In vivo</i> and <i>in vitro</i> effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity | 4.0 | 49 | Citations (PDF) |
| 103 | Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients | 2.0 | 13 | Citations (PDF) |
| 104 | Past, present and future of immunology in Mainz | 2.5 | 0 | Citations (PDF) |
| 105 | The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion | 7.9 | 26 | Citations (PDF) |
| 106 | Down-regulation of neuronal L1 cell adhesion molecule expression alleviates inflammatory neuronal injury | 7.9 | 12 | Citations (PDF) |
| 107 | Protein kinase CK2 governs the molecular decision between encephalitogenic T
<sub>H</sub>
17 cell and T
<sub>reg</sub>
cell development | 7.7 | 33 | Citations (PDF) |
| 108 | Increase of Alternatively Activated Antigen Presenting Cells in Active Experimental Autoimmune Encephalomyelitis | 3.1 | 11 | Citations (PDF) |
| 109 | NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk | 12.8 | 21 | Citations (PDF) |
| 110 | Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation | 11.3 | 110 | Citations (PDF) |
| 111 | Power estimation for non-standardized multisite studies | 4.8 | 32 | Citations (PDF) |
| 112 | Understanding the Role of T Cells in CNS Homeostasis | 15.9 | 121 | Citations (PDF) |
| 113 | Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology? | 13.4 | 83 | Citations (PDF) |
| 114 | Dendritic cells as therapeutic targets in neuroinflammation | 5.6 | 24 | Citations (PDF) |
| 115 | PML risk stratification using anti-JCV antibody index and L-selectin | 4.1 | 59 | Citations (PDF) |
| 116 | A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis | 3.9 | 10 | Citations (PDF) |
| 117 | Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression | 4.1 | 14 | Citations (PDF) |
| 118 | Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration | 4.1 | 44 | Citations (PDF) |
| 119 | Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2 | 2.2 | 29 | Citations (PDF) |
| 120 | Phenotype of Antigen Unexperienced TH Cells in the Inflamed Central Nervous System in Experimental Autoimmune Encephalomyelitis | 3.1 | 0 | Citations (PDF) |
| 121 | The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis | 2.5 | 14 | Citations (PDF) |
| 122 | No role of IFITM3 in brain tumor formation<i>in vivo</i> | 1.7 | 4 | Citations (PDF) |
| 123 | Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array | 3.2 | 14 | Citations (PDF) |
| 124 | New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosisBrain, 2015, 138, 902-917 | 8.9 | 54 | Citations (PDF) |
| 125 | A human post-mortem brain model for the standardization of multi-centre MRI studies | 4.8 | 26 | Citations (PDF) |
| 126 | Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo | 13.1 | 94 | Citations (PDF) |
| 127 | Genetic Cell Ablation Reveals Clusters of Local Self-Renewing Microglia in the Mammalian Central Nervous System | 22.7 | 497 | Citations (PDF) |
| 128 | Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis | 2.4 | 12 | Citations (PDF) |
| 129 | FRET based ratiometric Ca2+ imaging to investigate immune-mediated neuronal and axonal damage processes in experimental autoimmune encephalomyelitis | 2.4 | 11 | Citations (PDF) |
| 130 | Identification of cortical lesions using DIR and FLAIR in early stages of multiple sclerosis | 3.4 | 28 | Citations (PDF) |
| 131 | Putaminal alteration in multiple sclerosis patients with spinal cord lesions | 3.6 | 3 | Citations (PDF) |
| 132 | FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis | 4.1 | 34 | Citations (PDF) |
| 133 | Cross-Recognition of a Myelin Peptide by CD8<sup>+</sup>T Cells in the CNS Is Not Sufficient to Promote Neuronal Damage | 3.7 | 12 | Citations (PDF) |
| 134 | Genome-wide significant association with seven novel multiple sclerosis risk loci | 3.7 | 33 | Citations (PDF) |
| 135 | Long-Term Performance of the Bovine Pericardium Patch in Conventional Carotid Endarterectomy | 1.3 | 8 | Citations (PDF) |
| 136 | Class II HLA interactions modulate genetic risk for multiple sclerosis | 16.3 | 286 | Citations (PDF) |
| 137 | Role of Sortilin in Models of Autoimmune Neuroinflammation | 0.6 | 12 | Citations (PDF) |
| 138 | The impact of isolated lesions on white-matter fiber tracts in multiple sclerosis patients | 3.5 | 30 | Citations (PDF) |
| 139 | Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex | 3.8 | 47 | Citations (PDF) |
| 140 | Structural correlates for fatigue in early relapsing remitting multiple sclerosis | 3.8 | 50 | Citations (PDF) |
| 141 | Changes in brain functional connectivity patterns are driven by an individual lesion in MS: a resting-state fMRI study | 2.2 | 32 | Citations (PDF) |
| 142 | Microglia–blood vessel interactions: a double-edged sword in brain pathologies | 7.9 | 227 | Citations (PDF) |
| 143 | MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4 | 9.1 | 157 | Citations (PDF) |
| 144 | MHCII-independent CD4+ T cells protect injured CNS neurons via IL-4 | 9.1 | 45 | Citations (PDF) |
| 145 | Betreuung von Patienten mit multipler Sklerose 2015, , 393-402 | | 0 | Citations (PDF) |
| 146 | Neue, experimentelle und zukünftige Therapieansätze 2015, , 361-368 | | 0 | Citations (PDF) |
| 147 | Modulation of Dendritic Cell Immunobiology via Inhibition of 3-Hydroxy-3-Methylglutaryl-CoA (HMG-CoA) Reductase | 2.5 | 12 | Citations (PDF) |
| 148 | Experimental Applications of TNF-Reporter Mice with Far-Red Fluorescent Label | 0.0 | 5 | Citations (PDF) |
| 149 | How to treat tumefactive demyelinating disease? | 4.1 | 13 | Citations (PDF) |
| 150 | Molecular mechanisms linking neuroinflammation and neurodegeneration in MS | 4.1 | 136 | Citations (PDF) |
| 151 | A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility | 3.0 | 26 | Citations (PDF) |
| 152 | Remyelinating strategies in multiple sclerosis | 3.2 | 17 | Citations (PDF) |
| 153 | IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments | 10.5 | 111 | Citations (PDF) |
| 154 | Assessment of microRNA-related SNP effects in the 3′ untranslated region of the IL22RA2 risk locus in multiple sclerosis | 1.0 | 16 | Citations (PDF) |
| 155 | Cladribine exerts an immunomodulatory effect on human and murine dendritic cells | 4.1 | 31 | Citations (PDF) |
| 156 | Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis | 3.5 | 33 | Citations (PDF) |
| 157 | Perivascular microglia promote blood vessel disintegration in the ischemic penumbra | 7.9 | 195 | Citations (PDF) |
| 158 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis | 16.3 | 1,115 | Citations (PDF) |
| 159 | MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosisBrain, 2013, 136, 1778-1782 | 8.9 | 60 | Citations (PDF) |
| 160 | Neurons as targets for T cells in the nervous system | 13.4 | 85 | Citations (PDF) |
| 161 | Novel therapeutic options and drug targets in MS | 9.2 | 18 | Citations (PDF) |
| 162 | Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls | 6.8 | 135 | Citations (PDF) |
| 163 | Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosisBrain, 2013, 136, 1048-1066 | 8.9 | 97 | Citations (PDF) |
| 164 | Bilateral vertebral artery dissection, agenesis of both ICAs, and connective tissue aberrations | 1.3 | 3 | Citations (PDF) |
| 165 | Genome-wide significant association ofANKRD55rs6859219 and multiple sclerosis risk | 3.7 | 32 | Citations (PDF) |
| 166 | Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis | 14.3 | 26 | Citations (PDF) |
| 167 | Two-Photon Imaging of Immune Cells in Neural Tissue | 0.6 | 5 | Citations (PDF) |
| 168 | The Role of CD8+ T Cells and Their Local Interaction with CD4+ T Cells in Myelin Oligodendrocyte Glycoprotein35–55–Induced Experimental Autoimmune Encephalomyelitis | 0.6 | 27 | Citations (PDF) |
| 169 | Parallelized TCSPC for Dynamic Intravital Fluorescence Lifetime Imaging: Quantifying Neuronal Dysfunction in Neuroinflammation | 2.5 | 60 | Citations (PDF) |
| 170 | Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis | 2.5 | 42 | Citations (PDF) |
| 171 | Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis | 3.9 | 68 | Citations (PDF) |
| 172 | Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database | 3.3 | 461 | Citations (PDF) |
| 173 | Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany | 3.7 | 36 | Citations (PDF) |
| 174 | Closing the case of<i>APOE</i>in multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1 | 3.7 | 30 | Citations (PDF) |
| 175 | The problems and promises of research into human immunology and autoimmune disease | 25.6 | 46 | Citations (PDF) |
| 176 | Two laboratory-confirmed cases of Japanese encephalitis imported to Germany by travelers returning from Southeast Asia | 3.1 | 20 | Citations (PDF) |
| 177 | Neurodegeneration in multiple sclerosis: novel treatment strategies | 3.2 | 75 | Citations (PDF) |
| 178 | Rapid alterations of cell cycle control proteins in human T lymphocytes in microgravity | 8.1 | 70 | Citations (PDF) |
| 179 | Genetisches Profil der Multiplen Sklerose: Risikogene und die „dunkle Materie“ | 0.9 | 4 | Citations (PDF) |
| 180 | Mitoxantrone Induces Natural Killer Cell Maturation in Patients with Secondary Progressive Multiple Sclerosis | 2.5 | 18 | Citations (PDF) |
| 181 | Potential drug targets for oral medications 2012, , 18-38 | | 0 | Citations (PDF) |
| 182 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | 40.1 | 2,243 | Citations (PDF) |
| 183 | BLBP-expression in astrocytes during experimental demyelination and in human multiple sclerosis lesions | 4.3 | 71 | Citations (PDF) |
| 184 | MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas | 2.5 | 45 | Citations (PDF) |
| 185 | No Association Between Genetic Polymorphism at Codon 129 of the Prion Protein Gene and Primary Progressive Multiple Sclerosis | 6.8 | 3 | Citations (PDF) |
| 186 | Analyses of phenotypic and functional characteristics of CX3CR1‐expressing natural killer cells | 4.8 | 71 | Citations (PDF) |
| 187 | Neuroprotektion in der Therapie der Multiplen Sklerose | 0.9 | 1 | Citations (PDF) |
| 188 | Diagnostik der Multiplen Sklerose 2010 Revision der McDonald-Kriterien | 0.9 | 12 | Citations (PDF) |
| 189 | Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab | 0.9 | 13 | Citations (PDF) |
| 190 | In vivo imaging of lymphocytes in the CNS reveals different behaviour of naïve T cells in health and autoimmunity | 9.2 | 40 | Citations (PDF) |
| 191 | Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci | 6.6 | 291 | Citations (PDF) |
| 192 | Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study | 4.1 | 166 | Citations (PDF) |
| 193 | Intracranial spreading of a spinal anaplastic astrocytoma | 3.4 | 2 | Citations (PDF) |
| 194 | Independent replication of STAT3 association with multiple sclerosis risk in a large German case–control sample | 1.0 | 21 | Citations (PDF) |
| 195 | Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation | 2.5 | 77 | Citations (PDF) |
| 196 | In Vivo Imaging of Partially Reversible Th17 Cell-Induced Neuronal Dysfunction in the Course of Encephalomyelitis | 22.7 | 264 | Citations (PDF) |
| 197 | Dysregulated Epstein-Barr virus infection in patients with CIDP | 2.4 | 17 | Citations (PDF) |
| 198 | Neuronal injury in chronic CNS inflammation | 2.4 | 120 | Citations (PDF) |
| 199 | MAPK3 deficiency drives autoimmunity <i>via</i> DC arming | 3.5 | 21 | Citations (PDF) |
| 200 | Microgravity-induced alterations in signal transduction in cells of the immune system | 3.5 | 56 | Citations (PDF) |
| 201 | Correspondence to Sand et al. “Critical Reappraisal of a Catechol-O-Methyltransferase Transversion Variant in Schizophrenia” | 1.7 | 2 | Citations (PDF) |
| 202 | Expanding Two-Photon Intravital Microscopy to the Infrared by Means of Optical Parametric Oscillator | 0.4 | 85 | Citations (PDF) |
| 203 | Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients | 1.4 | 100 | Citations (PDF) |
| 204 | Multiple sclerosis – candidate mechanisms underlying CNS atrophy | 13.4 | 174 | Citations (PDF) |
| 205 | Neurodegeneration in autoimmune CNS inflammation | 4.1 | 89 | Citations (PDF) |
| 206 | MR-elastography reveals degradation of tissue integrity in multiple sclerosis | 4.8 | 258 | Citations (PDF) |
| 207 | Encephalopathy, visual disturbance and hearing loss—recognizing the symptoms of Susac syndrome | 9.2 | 56 | Citations (PDF) |
| 208 | Cytotoxic CD8<sup>+</sup>T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death | 3.7 | 78 | Citations (PDF) |
| 209 | A new light source for multimodal multiphoton microscopy including CARS 2009, , | | 1 | Citations (PDF) |
| 210 | SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT | 1.3 | 36 | Citations (PDF) |
| 211 | Differential immune cell dynamics in the CNS cause CD4+ T cell compartmentalizationBrain, 2009, 132, 1247-1258 | 8.9 | 60 | Citations (PDF) |
| 212 | Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis | 1.3 | 57 | Citations (PDF) |
| 213 | Neuroprotection and enhanced neurogenesis by extract from the tropical plant Knema laurina after inflammatory damage in living brain tissue | 2.4 | 18 | Citations (PDF) |
| 214 | Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis | 6.6 | 143 | Citations (PDF) |
| 215 | Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation | 3.6 | 47 | Citations (PDF) |
| 216 | Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system | 25.6 | 113 | Citations (PDF) |
| 217 | MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study | 3.8 | 30 | Citations (PDF) |
| 218 | ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosisBrain, 2009, 132, 2517-2530 | 8.9 | 64 | Citations (PDF) |
| 219 | Bilateral stroke following pituitary apoplexy | 1.7 | 12 | Citations (PDF) |
| 220 | A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes | 1.4 | 18 | Citations (PDF) |
| 221 | A woman with acute myelopathy in pregnancy: case outcome | 0.1 | 33 | Citations (PDF) |
| 222 | New developments in understanding and treating neuroinflammation | 3.6 | 36 | Citations (PDF) |
| 223 | Sirt1 contributes critically to the redox-dependent fate of neural progenitors | 10.5 | 400 | Citations (PDF) |
| 224 | Treatment-resistant chronic headaches and focal pachymeningitis in a 46-year-old man: a rare presentation of Wegener's granulomatosis | 19.1 | 13 | Citations (PDF) |
| 225 | Therapeutic targeting of chemokine signaling in Multiple Sclerosis | 1.4 | 31 | Citations (PDF) |
| 226 | Roles of the kallikrein/kinin system in the adaptive immune system | 4.1 | 26 | Citations (PDF) |
| 227 | Multiple sclerosis following etanercept treatment for ankylosing spondylitis | 1.6 | 30 | Citations (PDF) |
| 228 | Autoregulation of Th1-mediated inflammation by <i>twist1 </i> | 8.1 | 93 | Citations (PDF) |
| 229 | Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica | 1.5 | 286 | Citations (PDF) |
| 230 | Perivascular spaces--MRI marker of inflammatory activity in the brain?Brain, 2008, 131, 2332-2340 | 8.9 | 209 | Citations (PDF) |
| 231 | Celiac antibodies in the diagnostic workup of white matter lesions | 1.3 | 4 | Citations (PDF) |
| 232 | Neues zu Pathogenese, Diagnostik und Therapie der Neuromyelitis optica | 0.3 | 3 | Citations (PDF) |
| 233 | SFB TRR43: Das Gehirn als Ziel von entzündlichen Prozessen | 0.2 | 0 | Citations (PDF) |
| 234 | Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis | 2.5 | 99 | Citations (PDF) |
| 235 | Geranylgeranylation but Not GTP Loading Determines Rho Migratory Function in T Cells | 0.6 | 26 | Citations (PDF) |
| 236 | Neuronal Damage in Brain Inflammation | 6.8 | 198 | Citations (PDF) |
| 237 | Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy | 1.3 | 53 | Citations (PDF) |
| 238 | New Insights into Adaptive Immunity in Chronic Neuroinflammation | 0.0 | 42 | Citations (PDF) |
| 239 | Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery | 2.3 | 21 | Citations (PDF) |
| 240 | Impact of HMG-CoA reductase inhibition on brain pathology | 14.8 | 55 | Citations (PDF) |
| 241 | Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis | 2.0 | 42 | Citations (PDF) |
| 242 | Serum levels of soluble CD95 are not associated with amelioration of multiple sclerosis during pregnancy | 1.4 | 5 | Citations (PDF) |
| 243 | Cerebral blood perfusion changes in multiple sclerosis | 1.4 | 52 | Citations (PDF) |
| 244 | The role of TRAIL/TRAIL receptors in central nervous system pathology | 6.5 | 49 | Citations (PDF) |
| 245 | Mouse model mimics multiple sclerosis in the clinico-radiological paradox | 3.7 | 43 | Citations (PDF) |
| 246 | CNS‐irrelevant T‐cells enter the brain, cause blood–brain barrier disruption but no glial pathology | 3.7 | 48 | Citations (PDF) |
| 247 | Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets | 2.4 | 35 | Citations (PDF) |
| 248 | Neural Cell Adhesion Molecule Polysialylation Enhances the Sensitivity of Embryonic Stem Cell-Derived Neural Precursors to Migration Guidance Cues | 3.3 | 51 | Citations (PDF) |
| 249 | High-field diffusion tensor imaging of mouse brain in vivo using single-shot STEAM MRI | 2.4 | 19 | Citations (PDF) |
| 250 | Revised diagnostic criteria for neuromyelitis optica—incorporation of NMO-IgG status | 1.5 | 14 | Citations (PDF) |
| 251 | TRAIL limits excessive host immune responses in bacterial meningitis | 9.1 | 64 | Citations (PDF) |
| 252 | Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica | 8.1 | 182 | Citations (PDF) |
| 253 | Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a | 4.7 | 29 | Citations (PDF) |
| 254 | The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases | 13.4 | 306 | Citations (PDF) |
| 255 | Cell–cell communication by Endocannabinoids during Immune Surveillance of the Central Nervous System 2006, , 281-305 | | 7 | Citations (PDF) |
| 256 | Bilateral meralgia paresthetica after cesarian section with epidural analgesia | 3.8 | 9 | Citations (PDF) |
| 257 | A case of recurrent Miller Fisher syndrome mimicking botulism | 1.7 | 12 | Citations (PDF) |
| 258 | Rezidivierendes reversibles posteriores Leukenzephalopathiesyndrom unter Chemotherapie mit Cisplatin und 5-Fluorouracil | 0.9 | 6 | Citations (PDF) |
| 259 | Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans | 2.4 | 27 | Citations (PDF) |
| 260 | Neurodegeneration bei der Multiplen Sklerose | 0.1 | 0 | Citations (PDF) |
| 261 | Blockade of chemokine signaling in patients with multiple sclerosis | 1.3 | 59 | Citations (PDF) |
| 262 | Death Ligands and Autoimmune Demyelination | 4.7 | 35 | Citations (PDF) |
| 263 | Atorvastatin Induces T Cell Anergy via Phosphorylation of ERK1 | 0.6 | 53 | Citations (PDF) |
| 264 | Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate | 2.4 | 32 | Citations (PDF) |
| 265 | Modulating T cell signaling cascades by HMG-CoA reductase inhibitors | 0.6 | 3 | Citations (PDF) |
| 266 | Frequency of blood CX3CR1‐positive natural killer cells correlates with disease activity in multiple sclerosis patients | 0.7 | 81 | Citations (PDF) |
| 267 | Indolamine 2,3‐dioxygenase is expressed in the CNS and down‐regulates autoimmune inflammation | 0.7 | 248 | Citations (PDF) |
| 268 | Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL | 12.8 | 194 | Citations (PDF) |
| 269 | Multiple Sklerose – weit mehr als eine Entmarkungskrankheit | 0.2 | 0 | Citations (PDF) |
| 270 | Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study | 4.1 | 44 | Citations (PDF) |
| 271 | Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue | 3.7 | 124 | Citations (PDF) |
| 272 | Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI studyBrain, 2004, 127, 111-119 | 8.9 | 181 | Citations (PDF) |
| 273 | Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis | 0.6 | 296 | Citations (PDF) |
| 274 | Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis | 2.4 | 25 | Citations (PDF) |
| 275 | Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis | 3.4 | 17 | Citations (PDF) |
| 276 | A genome-wide German screen for linkage disequilibrium in multiple sclerosis | 2.4 | 7 | Citations (PDF) |
| 277 | Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients | 2.4 | 42 | Citations (PDF) |
| 278 | TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis | 35.3 | 181 | Citations (PDF) |
| 279 | Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin | 8.1 | 256 | Citations (PDF) |
| 280 | Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes | 3.5 | 94 | Citations (PDF) |
| 281 | Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation | 8.1 | 129 | Citations (PDF) |
| 282 | Ido (indolamine 2,3-dioxygenase) Expression and Function in the CNS | 0.0 | 43 | Citations (PDF) |
| 283 | Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy | 2.3 | 24 | Citations (PDF) |
| 284 | Death Ligand TRAIL Induces No Apoptosis but Inhibits Activation of Human (Auto)antigen-Specific T Cells | 0.6 | 116 | Citations (PDF) |
| 285 | Rhabdomyolysis during interferon-beta 1a treatment | 2.0 | 11 | Citations (PDF) |
| 286 | Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand But Presence of Its Receptors in the Human Brain | 3.7 | 99 | Citations (PDF) |
| 287 | Induction of TRAIL-mediated glioma cell death by human T cells | 2.4 | 23 | Citations (PDF) |
| 288 | Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis | 2.4 | 30 | Citations (PDF) |
| 289 | Investigation of bax, bcl-2, bcl-x and p53 gene polymorphisms in multiple sclerosis | 2.4 | 11 | Citations (PDF) |
| 290 | Astrocyte-induced T cell elimination is CD95 ligand dependent | 2.4 | 56 | Citations (PDF) |
| 291 | Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins | 3.3 | 43 | Citations (PDF) |
| 292 | Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose | 0.9 | 1 | Citations (PDF) |
| 293 | Aktuelle Empfehlungen zu Impfungen bei Multipler Sklerose | 0.9 | 2 | Citations (PDF) |
| 294 | Peripheral blood cell bulk cultures are not suitable for the analysis of the genetic control of T-cell cytokine function | 2.4 | 0 | Citations (PDF) |
| 295 | Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis | 2.4 | 41 | Citations (PDF) |
| 296 | Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells | 13.7 | 55 | Citations (PDF) |
| 297 | Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells | 2.4 | 28 | Citations (PDF) |
| 298 | Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells — implications for multiple sclerosis1This work was supported by grants from the DFG, the Hertie-Stiftung and the DMSG.1 | 2.4 | 4 | Citations (PDF) |
| 299 | Apoptose bei multipler Sklerose | 0.9 | 2 | Citations (PDF) |
| 300 | Apoptosis in multiple sclerosis | 2.8 | 65 | Citations (PDF) |
| 301 | Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2 | 1.0 | 22 | Citations (PDF) |
| 302 | Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) | 35.3 | 266 | Citations (PDF) |
| 303 | Immune (dys)regulation in multiple sclerosis: role of the CD95–CD95 ligand system | 8.9 | 67 | Citations (PDF) |
| 304 | No increase in demyelinating diseases after hepatitis B vaccination | 25.6 | 125 | Citations (PDF) |
| 305 | Title is missing! | 2.7 | 6 | Citations (PDF) |
| 306 | Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis | 6.6 | 71 | Citations (PDF) |
| 307 | Reply | 6.6 | 4 | Citations (PDF) |
| 308 | CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis | 2.4 | 23 | Citations (PDF) |
| 309 | Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis | 2.4 | 52 | Citations (PDF) |
| 310 | Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosisBrain, 1998, 121, 1395-1407 | 8.9 | 27 | Citations (PDF) |
| 311 | Multiple sclerosis: comparison of the human T-cell response to S100 beta and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitisBrain, 1997, 120, 1437-1445 | 8.9 | 49 | Citations (PDF) |
| 312 | Multiple Sklerose | 0.9 | 3 | Citations (PDF) |
| 313 | Genetic control of multiple sclerosis: Increased production of lymphotoxin and tumor necrosis factor-? by HLA-DR2+ T cells | 6.6 | 76 | Citations (PDF) |
| 314 | Lamotrigine in Parkinson's disease — a double blind study | 1.9 | 15 | Citations (PDF) |
| 315 | Lamotrigine-antiparkinsonian activity by blockade of glutamate release? | 1.9 | 33 | Citations (PDF) |
| 316 | Entorhinal fibers form synaptic contacts on parvalbumin-immunoreactive neurons in the rat fascia dentata | 2.5 | 92 | Citations (PDF) |
| 317 | Genetik neuroimmunologischer Erkrankungen 0, , | | 0 | Citations (PDF) |
